These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 33247945

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT.
    Int J Cardiol; 2016 Aug 01; 216():85-91. PubMed ID: 27140341
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S, Roessig L, Sandner P, Lewis KS.
    Handb Exp Pharmacol; 2017 Aug 01; 243():225-247. PubMed ID: 27900610
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J.
    Basic Res Cardiol; 2014 Jul 01; 109(4):421. PubMed ID: 24907870
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
    Shea CM, Price GM, Liu G, Sarno R, Buys ES, Currie MG, Masferrer JL.
    Am J Physiol Renal Physiol; 2020 Jan 01; 318(1):F148-F159. PubMed ID: 31608671
    [Abstract] [Full Text] [Related]

  • 16. Chronic circadian rhythm disorder induces heart failure with preserved ejection fraction-like phenotype through the Clock-sGC-cGMP-PKG1 signaling pathway.
    Che Y, Shimizu Y, Hayashi T, Suzuki J, Pu Z, Tsuzuki K, Narita S, Shibata R, Murohara T.
    Sci Rep; 2024 May 11; 14(1):10777. PubMed ID: 38734687
    [Abstract] [Full Text] [Related]

  • 17. Inactivation of soluble guanylyl cyclase in living cells proceeds without loss of haem and involves heterodimer dissociation as a common step.
    Dai Y, Stuehr DJ.
    Br J Pharmacol; 2022 Jun 11; 179(11):2505-2518. PubMed ID: 33975383
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The disruption of invariant natural killer T cells exacerbates cardiac hypertrophy and failure caused by pressure overload in mice.
    Takahashi M, Kinugawa S, Takada S, Kakutani N, Furihata T, Sobirin MA, Fukushima A, Obata Y, Saito A, Ishimori N, Iwabuchi K, Tsutsui H.
    Exp Physiol; 2020 Mar 11; 105(3):489-501. PubMed ID: 31957919
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.